1. Home
  2. CBT vs ACAD Comparison

CBT vs ACAD Comparison

Compare CBT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBT
  • ACAD
  • Stock Information
  • Founded
  • CBT 2019
  • ACAD 1993
  • Country
  • CBT United States
  • ACAD United States
  • Employees
  • CBT N/A
  • ACAD N/A
  • Industry
  • CBT Major Chemicals
  • ACAD Biotechnology: Pharmaceutical Preparations
  • Sector
  • CBT Industrials
  • ACAD Health Care
  • Exchange
  • CBT Nasdaq
  • ACAD Nasdaq
  • Market Cap
  • CBT 4.0B
  • ACAD 4.1B
  • IPO Year
  • CBT N/A
  • ACAD 2004
  • Fundamental
  • Price
  • CBT $61.37
  • ACAD $24.09
  • Analyst Decision
  • CBT Hold
  • ACAD Buy
  • Analyst Count
  • CBT 3
  • ACAD 21
  • Target Price
  • CBT $79.33
  • ACAD $29.10
  • AVG Volume (30 Days)
  • CBT 488.1K
  • ACAD 1.7M
  • Earning Date
  • CBT 11-03-2025
  • ACAD 11-05-2025
  • Dividend Yield
  • CBT 2.92%
  • ACAD N/A
  • EPS Growth
  • CBT N/A
  • ACAD 98.53
  • EPS
  • CBT 6.02
  • ACAD 1.54
  • Revenue
  • CBT $3,713,000,000.00
  • ACAD $1,047,118,000.00
  • Revenue This Year
  • CBT $6.09
  • ACAD $14.12
  • Revenue Next Year
  • CBT $3.05
  • ACAD $11.80
  • P/E Ratio
  • CBT $10.23
  • ACAD $15.58
  • Revenue Growth
  • CBT N/A
  • ACAD 12.69
  • 52 Week Low
  • CBT $58.99
  • ACAD $13.40
  • 52 Week High
  • CBT $115.16
  • ACAD $26.65
  • Technical
  • Relative Strength Index (RSI)
  • CBT 29.02
  • ACAD 61.73
  • Support Level
  • CBT $60.03
  • ACAD $22.00
  • Resistance Level
  • CBT $62.57
  • ACAD $23.58
  • Average True Range (ATR)
  • CBT 1.94
  • ACAD 1.03
  • MACD
  • CBT -0.10
  • ACAD 0.24
  • Stochastic Oscillator
  • CBT 19.90
  • ACAD 90.93

About CBT Cabot Corporation

Cabot Corp manufactures and sells a variety of chemicals, materials, and chemical-based products. The company organizes itself into the following operating segments based on the product type; the Reinforcement Materials segment which generates maximum revenue provides reinforcing carbon products used in tires, and industrial products such as hoses, belts, extruded profiles, and molded goods; and the Performance Chemicals segment aggregates the specialty carbons, specialty compounds, fumed metal oxides, battery materials, inkjet colorants, and aerogel product lines. Geographically, the company derives maximum revenue from its customers in Europe, the Middle East, and Africa and the rest from the Americas and Asia Pacific region.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: